These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 27741201

  • 1. Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
    Stetson B, Hibbard JU, Wilkins I, Leftwich H.
    Obstet Gynecol; 2016 Nov; 128(5):983-988. PubMed ID: 27741201
    [Abstract] [Full Text] [Related]

  • 2. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
    Massa K, Childress K, Vricella LK, Boerrigter A, Franklin BHK, Sauer M, Armbruster R, Tomlinson T.
    Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
    Mainiero AD, Rouse DJ, Lopes V, Hughes BL.
    Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
    [Abstract] [Full Text] [Related]

  • 6. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A, Vladutiu CJ, Dotters-Katz SK, Goodnight WH, Manuck TA.
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [Abstract] [Full Text] [Related]

  • 7. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, Huang H, Varner MW, Andrews W, Saade G, Sadovsky Y, Reddy UM, Ilekis J, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR).
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
    Saghafi N, Khadem N, Mohajeri T, Shakeri MT.
    J Obstet Gynaecol Res; 2011 Oct; 37(10):1342-5. PubMed ID: 21564406
    [Abstract] [Full Text] [Related]

  • 9. Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
    Caritis SN, Costantine MM, Clark S, Stika CS, Kiley JW, Metz TD, Chauhan SP, Venkataramanan R, Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Centers Network.
    Am J Obstet Gynecol MFM; 2023 Jul; 5(7):100980. PubMed ID: 37100349
    [Abstract] [Full Text] [Related]

  • 10. Adjuvant 17-hydroxyprogesterone caproate in women withultrasound-indicated cerclage: a systematic review and meta-analysis.
    Lichter KE, Sheffield J, Graham EM, Eke AC.
    J Matern Fetal Neonatal Med; 2020 Sep; 33(18):3177-3184. PubMed ID: 30626240
    [Abstract] [Full Text] [Related]

  • 11. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
    Quist-Nelson J, Parker P, Mokhtari N, Di Sarno R, Saccone G, Berghella V.
    Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
    [Abstract] [Full Text] [Related]

  • 12. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO, Stamilio DM, Macones GA, Polsky D.
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [Abstract] [Full Text] [Related]

  • 13. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
    Rebarber A, Cleary-Goldman J, Istwan NB, Rhea DJ, Desch C, Russo-Stieglitz K, Saltzman DH.
    Am J Perinatol; 2008 May; 25(5):271-5. PubMed ID: 18401840
    [Abstract] [Full Text] [Related]

  • 14. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA, Stoddard GJ, Fry RC, Esplin MS, Varner MW.
    Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [Abstract] [Full Text] [Related]

  • 15. A randomized trial of cerclage vs. 17 alpha-hydroxyprogesterone caproate for treatment of short cervix.
    Keeler SM, Kiefer D, Rochon M, Quinones JN, Novetsky AP, Rust O.
    J Perinat Med; 2009 Nov; 37(5):473-9. PubMed ID: 19492920
    [Abstract] [Full Text] [Related]

  • 16. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
    Edwards AM, Lowry SA, Mikovich S, Forinash AB, Babbar S.
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
    Mackeen AD, Rafael TJ, Zavodnick J, Berghella V.
    Am J Perinatol; 2013 Oct; 30(9):755-8. PubMed ID: 23341330
    [Abstract] [Full Text] [Related]

  • 18. Concurrent progestogen and cerclage to reduce preterm birth: a multicenter international retrospective cohort.
    Tolosa JE, Boelig RC, Bell J, Martínez-Baladejo M, Stoltzfus J, Mateus J, Quiñones JN, Galeano-Herrera S, Pereira L, Burwick R, López-Torres L, Valencia C, Berghella V, IC-CLEAR: International Collaborative for Cerclage Longitudinal Evaluation and Research.
    Am J Obstet Gynecol MFM; 2024 Jul; 6(7):101351. PubMed ID: 38513806
    [Abstract] [Full Text] [Related]

  • 19. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
    Eke AC, Sheffield J, Graham EM.
    Obstet Gynecol; 2019 Mar; 133(3):468-475. PubMed ID: 30741815
    [Abstract] [Full Text] [Related]

  • 20. The Effect of Intramuscular 17α-Hydroxyprogesterone in Women Screened for Shortened Cervical Length.
    Wood SL, Williams BN, Szychowski JM, Owen J.
    Am J Perinatol; 2020 Jun; 37(7):659-665. PubMed ID: 31756763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.